TLSA
Tiziana Life Sciences Ltd (NASDAQ)
Healthcare — Biotechnology
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Price History
Fundamentals
| Market Cap | $159.07M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.26 |
| EPS (TTM) | $-0.16 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -924.32% |
| Debt/Equity | 876.92 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $9.11 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 63.6 |
| Beta | 0.42 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.60 |
| 52-Week Low | $1.04 |
| 50-Day Avg | $1.31 |
| 200-Day Avg | $1.53 |
| Avg Volume | 208.3K |
| Volume | 2.9K |
Performance Analysis
BULLISHTLSA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report